Glaucoma QOL questionnaire ticks the right boxes

Article

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension.

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension (OHT), according to the results of a study published online ahead of print by Acta Ophthalmologica Scandinavica.

Alain Béchetoille from Paris and colleagues from across France enrolled patients with OHT or glaucoma (n=573) to take part in a cross-sectional psychometric validation study and a separate reproducibility study (n=244). Each subject answered the 36-item Glau-Qol questionnaire, which was designed from in-depth patient interviews.

The clinical validity of the questionnaire was found to be excellent. It clearly demonstrated that as disease severity and visual field impairment increased, health-related quality of life (HRQoL) scores from psychological wellbeing, self-image, daily life, driving, anxiety and burden of treatment domains were negatively affected. Increased age and lower visual acuity were also associated with lower HRQoL scores but to a lesser extent.

Psychometric validation demonstrated acceptable convergent and discriminant validity of the Glau-QoL and good reproducibility, with intra-class correlation coefficients and concordance correlation coefficients ≥0.69.

It was the conclusion of the researchers that the Glau-QoL questionnaire is a valid instrument that demonstrates excellent correlations with disease progression in patients with glaucoma and OHT.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.